Development and characterization of an enhanced nonviral expression vector for electroporation cancer treatment

Forde, Patrick F, Hall, Lindsay J ORCID:, Sadadcharam, Mira, de Kruijf, Marcle, O’ Sullivan, Gerald C and Soden, Declan M (2014) Development and characterization of an enhanced nonviral expression vector for electroporation cancer treatment. Molecular Therapy — Methods & Clinical Development, 1. ISSN 2329-0501

[thumbnail of mtm201412 (3)]
PDF (mtm201412 (3)) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (994kB) | Preview


Nonviral plasmid DNA gene therapy represents a promising approach for the treatment of many diseases including cancer. Intracellular delivery of DNA can be achieved with the application of electroporation, which facilitates the initial transport of exogenous DNA across the cell membrane into the cytoplasm. However, it does not guarantee further transport of the DNA from the cytoplasm to the nucleus for subsequent mRNA expression, resulting in varying degrees of exogenous gene translation and a major limitation in comparison to viral approaches. To overcome these expression difficulties, we developed a proof-of-concept vector enhanced expression vector (EEV), which incorporates elements from viral systems including nuclear localization sequences and a viral replicase from the Semliki Forest virus. The replicase allows for cytoplasmic mRNA expression and bypasses the need for nuclear localization to generate high levels of gene expression. We have demonstrated that our EEV is capable of achieving high levels of expression in a variety of tissue types. Antitumor effects of pEEV were demonstrated by the delayed growth and increased survival of the nontherapeutic pEEV-treated CT26 tumor model. Using a novel endoscopic electroporation system, EndoVe, we demonstrate and compare, for the first time, both standard cytomegalovirus (CMV) promoter-driven plasmid and EEV gene expression in intraluminal porcine tissues. Our EEV plasmid displays reliable and superior expression capability, and due to its inherent induced oncolytic activity in transfected cells, it may enhance the efficacy and safety of several cancer immunogene therapy approaches.

Item Type: Article
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User: Pure Connector
Date Deposited: 01 Aug 2014 14:16
Last Modified: 24 Oct 2022 23:57
DOI: 10.1038/mtm.2014.12


Downloads per month over past year

Actions (login required)

View Item View Item